Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Hormone replacement therapy is associated with gastro-oesophageal reflux disease: a retrospective cohort study.

Close H, Mason JM, Wilson D, Hungin AP.

BMC Gastroenterol. 2012 May 29;12:56. doi: 10.1186/1471-230X-12-56.

2.

Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey.

Toghanian S, Johnson DA, Stålhammar NO, Zerbib F.

Clin Drug Investig. 2011 Oct 1;31(10):703-15. doi: 10.2165/11595480-000000000-00000.

PMID:
21756007
3.

Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution.

Norman RJ, Flight IH, Rees MC.

Cochrane Database Syst Rev. 2000;(2):CD001018. Review.

PMID:
10796730
4.

Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease.

Benson VS, Müllerová H, Vestbo J, Wedzicha JA, Patel A, Hurst JR; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators..

Respir Med. 2015 Sep;109(9):1147-54. doi: 10.1016/j.rmed.2015.06.009. Epub 2015 Jun 23.

PMID:
26166017
5.

Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.

Alexandropoulou K, van Vlymen J, Reid F, Poullis A, Kang JY.

Eur J Gastroenterol Hepatol. 2013 Jan;25(1):15-21. doi: 10.1097/MEG.0b013e3283595086.

PMID:
23022985
6.

Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy.

Magnusson C, Baron JA, Correia N, Bergström R, Adami HO, Persson I.

Int J Cancer. 1999 May 5;81(3):339-44.

7.

Pharmacological treatment of children with gastro-oesophageal reflux.

Tighe M, Afzal NA, Bevan A, Hayen A, Munro A, Beattie RM.

Cochrane Database Syst Rev. 2014 Nov 24;(11):CD008550. doi: 10.1002/14651858.CD008550.pub2. Review.

PMID:
25419906
8.

Gastro-oesophageal reflux disease (GORD) in Australian general practice patients.

Miller G, Wong C, Pollack A.

Aust Fam Physician. 2015 Oct;44(10):701-4.

9.

Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME.

Cochrane Database Syst Rev. 2013 May 31;(5):CD002095. doi: 10.1002/14651858.CD002095.pub5. Review.

PMID:
23728637
10.

Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002095. doi: 10.1002/14651858.CD002095.pub4. Review. Update in: Cochrane Database Syst Rev. 2013;5:CD002095.

PMID:
21069670
11.

Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults.

Garg SK, Gurusamy KS.

Cochrane Database Syst Rev. 2015 Nov 5;(11):CD003243. doi: 10.1002/14651858.CD003243.pub3. Review.

PMID:
26544951
12.

Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults.

Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004823. doi: 10.1002/14651858.CD004823.pub4. Review.

PMID:
21249664
13.

Myocardial infarction risk and hormone replacement: differences between products.

de Vries CS, Bromley SE, Farmer RD.

Maturitas. 2006 Feb 20;53(3):343-50. Epub 2005 Jul 22.

PMID:
16040209
14.

Hormone replacement therapy and the risk of breast cancer.

Cuzick J.

Eur J Cancer. 2008 Nov;44(16):2344-9. doi: 10.1016/j.ejca.2008.07.041. Epub 2008 Sep 8. Review.

PMID:
18783940
15.

Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer?

Menon S, Nightingale P, Trudgill N.

United European Gastroenterol J. 2014 Oct;2(5):374-82. doi: 10.1177/2050640614543736.

16.

Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.

Renoux C, Dell'aniello S, Garbe E, Suissa S.

BMJ. 2010 Jun 3;340:c2519. doi: 10.1136/bmj.c2519.

17.

Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease.

Zerbib F, Belhocine K, Simon M, Capdepont M, Mion F, Bruley des Varannes S, Galmiche JP.

Gut. 2012 Apr;61(4):501-6. doi: 10.1136/gutjnl-2011-300798. Epub 2011 Oct 13.

PMID:
21997546
18.

Tibolone and endometrial cancer: a cohort and nested case-control study in the UK.

de Vries CS, Bromley SE, Thomas H, Farmer RD.

Drug Saf. 2005;28(3):241-9.

PMID:
15733028
19.

Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.

Kahrilas PJ, Hughes N, Howden CW.

Gut. 2011 Nov;60(11):1473-8. doi: 10.1136/gut.2011.241307. Epub 2011 Apr 20. Review.

PMID:
21508423
20.

Supplemental Content

Support Center